Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
14 auth.
M. Debiec-Rychter,
H. Dumez,
I. Judson,
B. Wasąg,
J. Verweij,
M. Brown,
S. Dimitrijević,
R. Sciot,
M. Stul,
H. Vranck,
...
M. Scurr,
A. Hagemeijer,
M. Glabbeke,
A. Oosterom
|
|
8 |
2004 |
Social Media Posts